Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Find generic entry opportunities
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Pharmaceutical growth hormone formulations|
|Abstract:||Parenteral pharmaceutical formulations of human growth hormone, which are stabilized against aggregation, comprising biosynthetic human growth hormone, glycine, and mannitol. Methods of reducing aggregation of human growth hormone in parenteral formulations are also provided.|
|Inventor(s):||Pikal; Michael J. (Greenwood, IN), Roy; Michael L. (Indianapolis, IN)|
|Assignee:||Eli Lilly and Company (Indianapolis, IN)|
Patent Claim Types:|
see list of patent claims
|Formulation; Compound; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.